Chemistry:Suzetrigine
From HandWiki
Short description: Investigational analgesic drug
 | |
| Clinical data | |
|---|---|
| Other names | VX-548 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H20F5N3O4 |
| Molar mass | 473.400 g·mol−1 |
Suzetrigine (VX-548) is a non-opioid, small-molecule analgesic that works as a selective inhibitor of Nav1.8.[1] It is being developed by Vertex Pharmaceuticals and is currently in Phase III trials.[2]
Vertex announced in January 2024 that VX-548 successfully met several enpoints in its Phase III trials. The drug relieved moderate to severe post-surgical pain. Vertex hopes the drug, which operates on peripheral nerves, will avoid the addictive potential of opioids.[3][4]
See also
References
- ↑ Jones, Jim; Correll, Darin J.; Lechner, Sandra M.; Jazic, Ina; Miao, Xiaopeng; Shaw, David; Simard, Christopher; Osteen, Jeremiah D. et al. (3 August 2023). "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain". The New England Journal of Medicine 389 (5): 393–405. doi:10.1056/NEJMoa2209870. ISSN 1533-4406. PMID 37530822. https://pubmed.ncbi.nlm.nih.gov/37530822/.
- ↑ "VX-548 by Vertex Pharmaceuticals for Neuropathic Pain (Neuralgia): Likelihood of Approval". Pharmaceutical Technology. 4 March 2023. https://www.pharmaceutical-technology.com/data-insights/vx-548-vertex-pharmaceuticals-neuropathic-pain-neuralgia-likelihood-of-approval/.
- ↑ Vertex Pharmaceuticals Incorporated Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain. Press Release, Jan 30, 2024.
- ↑ Kolata, Gina (30 January 2024). "Experimental Drug Cuts Off Pain at the Source, Company Says". The New York Times. https://www.nytimes.com/2024/01/30/health/vertex-pain-medicine-non-opioid.html.
 |  |
